Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Recombinant Human Thymosin Beta 4 in Acute Myocardial Infarction
NCT05485818Phase 2Completed
- Sponsor
- Northland Biotech
- Start
- Nov 2020
- Primary completion
- Sep 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of thymosin beta-4 in acute myocardial infarction (AMI), sponsored by Northland Biotech. Started Nov 2020; status: completed.
02
Drugs
thymosin beta-4
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT05485818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05485818.